// App-Quantinova.ai

DXT50 : Prevalence of Serious Adverse Pregnancy Outcomes after Exposure to Interferon Beta before or during Pregnancy: Stratification By Characteristics of Pregnant Women with MS in a Register-Based Cohort Study in Finland and Sweden

Researchers

Presenter

  • Marta Korjagina

Principal Investigators

  • Katja Hakkarainen

  • Sarah Burkill

  • Yvonne Geissbuehler

  • Meritxell Sabidó

  • Achint Kumar

  • Kiliana Suzart-Woischnik

  • Riho Klement

  • Jan Hillert

  • Auli Verkkoniemi-Ahola

  • Shahram Bahmanyar

  • Scott Montgomery

  • Pasi Korhonen

Medical Centers

  • Karolinska Institutet,

  • Karolinska Institute Orebro University University College London

  • Helsinki University Hospital; University of Helsinki

  • Novartis Pharma AG

Locations

  • United Kingdom

  • Finland

Companies

  • N/A

Study Components

Therapeutic Area

  • Congenital disorder

  • Genetic Disorder

Disease

  • Congenital anomalies

Biomarkers

  • Interferon

Drug/Treatment

  • Interferon Beta

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved